Wednesday, August 26, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Aug 25, 2026
Why a Texas congressman believes Chinese biotechs are 'beating us on our ground game'
background ▾
- •Chinese biotech assets are projected to dominate two-thirds of global licensing deal value in 2024, representing a dramatic shift in pharmaceutical IP and R&D control driven by profit-seeking U.S. investors
- •Congress is advancing bipartisan legislation (BINSA) to restrict U.S. outbound investment in Chinese biotechnology and increase scrutiny of clinical trials, manufacturing, and active pharmaceutical ingredient sourcing
- •Watch for passage and enforcement of BINSA and similar legislation, potential restrictions on U.S. VC funding flows into Chinese biotech, and changes to FDA/CFIUS review of China-linked deals and trials
Policy•Fierce Biotech•Aug 25, 2026
Implantica finally nabs FDA approval 8 years after EU green light for reflux implant
background ▾
- •FDA approval of RefluxStop opens access to a massive U.S. GERD market (78 million patients) after successful 5-year PMA clinical data review, positioning the device as an alternative to long-term pharmacotherapy for select patients
- •European commercial validation demonstrates viability: 1,800+ patients treated across 60+ centers since 2018 and 60%+ year-over-year sales growth in key European markets de-risks U.S. adoption
- •Watch for: surgical adoption rate and reimbursement coverage decisions from major U.S. payers, which will be critical determinants of scaling success given the invasive nature and need for specialized surgeon training
ImplanticaRefluxStop
→ Read original articlePolicy•STAT News•Aug 26, 2026
Opinion: Many post-Dobbs abortion fears have not come to pass. What does that mean for advocates?
background ▾
- •Infant mortality has demonstrably risen 5.6% in states with heavy abortion restrictions, primarily due to forced continuation of nonviable pregnancies and high-risk conditions
- •National maternal mortality rates have remained stable post-Dobbs despite initial predictions of widespread increases, though regional disparities exist and aggregate data may obscure vulnerable populations
mifepristone
→ Read original articlePolicy•STAT News•Aug 26, 2026
Opinion: Medical aid in dying and the burden of choosing to live
background ▾
- •New York's MAiD law includes an audio/video recording requirement for patient requests, designed to ensure genuine patient autonomy in decision-making
Policy•Endpoints News•Aug 25, 2026
Amgen, academic centers weigh new FDA pilot to speed early drug trials
background ▾
- •FDA is piloting a program with industry and academic partners to streamline early-phase trial approval, responding to competitive pressure from China and Australia's faster trial startup timelines
- •Current U.S. regulatory delays in Phase 1 review are incentivizing sponsors to initiate first-in-human studies abroad, representing a strategic vulnerability for American biotech infrastructure
- •Monitor pilot program parameters, participating institutions, and whether accelerated early-phase review becomes permanent FDA policy
Amgen
→ Read original articleMarket Access
Market Access•Fierce Biotech•Aug 26, 2026
SK Biopharma pens $795M deal to usher Biohaven’s epilepsy therapy towards hoped-for 2029 launch
background ▾
- •SK acquires opakalim for up to $795M total consideration, with $400M in near-term payments, positioning it as a strategic addition to SK's epilepsy portfolio alongside Xcopri
- •Opakalim phase 2/3 topline data expected later this year; open-label extension showed 54% seizure reduction at 75mg daily with favorable tolerability profile versus competitors including azetukalner
- •Watch for phase 2/3 trial readout imminently; competitive landscape tightens as azetukalner advances in late-stage development; SK's commercial execution and regulatory pathway clarity in 2024-2025
SK BiopharmaceuticalsSK Life ScienceBiohaven PharmaceuticalsopakalimBHV-7000Xcopri
→ Read original articleMarket Access•Fierce Biotech•Aug 25, 2026
Founded by Metsera backers, Sentivera emerges with $1.5B inflammatory disease deal
background ▾
- •Sentivera's $1.5B deal validates a rapid capital deployment strategy by proven VCs targeting high-value inflammatory disease markets, leveraging lessons from the Metsera-Pfizer exit
- •Haisco's dual role—as equity holder (17.5%), uplift provider, and retained regional rights holder—creates aligned incentives but also concentrates risk in a single Chinese pharma partner with limited disclosed development data
- •The identity and mechanism of the inflammatory disease candidate remain proprietary; clinical progress in China and subsequent global development will be critical indicators of deal value realization
SentiveraArch Venture PartnersPopulation Health PartnersDupixent
→ Read original articleMarket Access•Endpoints News•Aug 25, 2026
Sword Health plans to buy Headspace, filing says
background ▾
- •Sword Health and Headspace merger would consolidate two major digital health platforms with complementary mental and physical health focus
Sword HealthHeadspace
→ Read original articleMarket Access•Fierce Biotech•Aug 25, 2026
Labcorp launches new hepatitis D test to find patients with most severe form of virus
background ▾
- •Labcorp's reflex testing addresses a major care gap: <20% of hepatitis B patients are tested for HDV despite 70,000–150,000 active infections in the U.S., contributing to delayed diagnosis and treatment initiation.
- •Direct competition emerging: Roche's cobas HDV test (launched last month) and Gilead's Hepcludex approval (May) indicate intensifying diagnostic and therapeutic attention to HDV.
- •Watch for: Adoption rates among clinicians, impact on patient identification and linkage to Hepcludex therapy, and whether payer coverage/reimbursement accelerates.
LabcorpRocheGileadHepcludex
→ Read original articleMarket Access•Endpoints News•Aug 25, 2026
ARCH and Population Health join China blitz with Haisco deal
background ▾
- •Haisco Pharmaceuticals is actively pursuing multiple partnerships to expand its commercial footprint
- •The involvement of two established biotech players (ARCH and Population Health) suggests Haisco is pursuing meaningful market access or distribution partnerships
Haisco PharmaceuticalsARCHPopulation Health
→ Read original articleClinical Trials
Clinical Trials•Endpoints News•Aug 24, 2026
Regenxbio hit with another clinical hold for Hunter syndrome gene therapy
background ▾
- •Clinical hold placed on Regenxbio's Hunter syndrome gene therapy eliminates near-term filing prospects
- •No public disclosure of hold rationale or remediation pathway raises questions about underlying safety or efficacy concerns
- •Outcome will determine whether rare disease gene therapy pipeline advances or requires fundamental program restructuring
RegenxbioHunter syndrome gene therapy
→ Read original articleClinical Trials•STAT News•Aug 26, 2026
Newer shingles vaccine linked to lower heart disease risk, ‘natural experiment’ shows
background ▾
- •Shingrix demonstrates a 9% lower overall cardiovascular burden versus Zostavax, with coronary heart disease reduced 10% and heart failure reduced 12% over seven years in a natural experiment design that reduces healthy vaccine bias
- •The study's natural experiment methodology—comparing matched cohorts vaccinated before and after October 2017 approval—provides stronger evidence than traditional observational studies but remains non-causal
- •A large randomized controlled trial (DAN ZOSTER, 162,000 participants) is underway in Denmark with results anticipated in 2027; confirmation could position Shingrix as a vaccine protecting both cardiovascular and cognitive health
GSKShingrixZostavax
→ Read original articleClinical Trials•Fierce Biotech•Aug 26, 2026
Spyre’s rheumatoid arthritis plan toppled by subpar TL1A data
background ▾
- •SPY072 missed primary efficacy targets in RA with placebo-adjusted DAS28-CRP reductions of only 0.2–0.6 points (vs. 1.0-point target) and ACR20 improvements of only 15–20 percentage points (vs. 30-point target), with only low-dose DAS28-CRP achieving statistical significance.
- •Spyre is shifting strategy away from RA monotherapy to focus on combination approaches (notably with Bimzelx) and other autoimmune indications (psoriatic arthritis, axial spondyloarthritis, UC), where TL1A mechanism has stronger preliminary evidence.
- •Q4 2024 Phase 2 readouts in psoriatic arthritis and axial spondyloarthritis, plus competitive Phase 2/3 data from Merck, Roche, and Sanofi in rheumatic and bowel disease indications, will determine whether TL1A inhibition can be salvaged outside UC/Crohn's disease.
Spyre TherapeuticsMerck & Co.RocheSPY072SPY002Bimzelx
→ Read original article